LYTIX (LYTIX) News
Follow LYTIX (LYTIX) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 4 public stories across 2 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
H
FDA clears Phase III path for Lytix ruxotemitide
FDA cleared the Phase III development path for ruxotemitide in Lytix Biopharma’s program.
REGULATION | Aug 28, 2026, 04:24 PM UTC
M
Lytix wins FDA approval for phase III melanoma trial
FDA approval for a phase III melanoma trial clears a path for partnership focus at Lytix.
REGULATION | Aug 27, 2026, 01:28 PM UTC
M
Lytix gets FDA clearance for registrational Phase III melanoma path
Lytix says the FDA cleared its registrational Phase III path in melanoma.
REGULATION | Aug 27, 2026, 12:58 PM UTC
M
Lytix gets FDA Phase III clearance for ruxotemitide
FDA cleared Phase III for ruxotemitide. Lytix says its cash position supports advancing the clinical pipeline.
REGULATION | Aug 27, 2026, 05:04 AM UTC